drugset / Trial / NCT03969823
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC
Active not recruiting
148 enrolled
Seoul National University Hospital
SMG-SNU Boramae Medical Center · collabSeoul National University Bundang Hospital · collab
NaSingle-groupOpen-labelOther
Summary
This is a phase 2 single-arm, non-randomized multicentre and tissue acquisition study to evaluate acquired resistance mechanisms, efficacy, and safety in advanced, EGFR tyrosine kinase inhibitor-naïve NSCLC patients with EGFR-activating mutations who receive a first-line osimertinib orally at a dose of 80mg once daily.
Timeline
- Start
- 2019-05-23
- Primary completion
- 2026-09-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | 80 mg | Oral |
Indications
No indication recorded.